Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

By J. Verweij, P. Casali, J. Zalcberg, A. Lecesne, P. Reichardt, Jean-Yves Blay, R. Issels, A. van Oosterom, P. Hogendoorn, M. V. Van Glabbeke and 2 more. The Lancet, 2004

1,513 citations recorded by the source corpus.

Subfields: Gastroenterology, Surgery

View Paper: https://www.semanticscholar.org/paper/2a3a00a1d2d72f07271a130b372e2b404eea1b52

Citations in the corpus

• Gastrointestinal stromal tumours: origin and molecular oncology (2011, neutral): “Overall, imatinib achieved disease control in 70–85% of patients with advanced KIT-positive GISTs, and the median progression-free survival was 20–24 month”
• Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. (2007, neutral): “Gleevec is indicated for chronic lymphocytic leukemia with BCR-ABL translocations [13] and for gastrointestinal stromal tumors (GISTs) with activating KIT mutations [14].”
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008, neutral): “A somewhat larger EORTC phase III trial, utilizing identical treatment arms, initially reported a statistically significant improvement in progression-free survival for patients with GISTs who received 800 mg of daily imatinib.(17) With further follow-up, the difference in progression-free survival ”
• One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. (2012, neutral): “Primary tumor diameter, median (range), cm 9 (2-35) 10 (2-40)”